menu-iconMore mobile-close-icon
Skip Navigation
Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC

Announcements

February 13, 2012

Newly Submitted



Health Awareness Topics - February 2012



NGC Spotlight


See the updated Mobile Resources page for information concerning the availability of full-text guidelines and/or companion documents available in downloadable versions for hand-held devices.

Conference News


The Guidelines International Network (G-I-N) Conference 2012, will be held August 22-25, 2012 in Berlin, Germany. Registration External Web Site Policy is now open.

U.S. Food and Drug Administration (FDA) Advisories


  • February 9, 2012: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs External Web Site Policy: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together.
  • February 8, 2012: Proton Pump Inhibitors (PPIs) External Web Site Policy: FDA notified the public that the use of stomach acid drugs known as proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea (CDAD). A diagnosis of CDAD should be considered for patients taking PPIs who develop diarrhea that does not improve. The FDA is working with manufacturers to include information about the increased risk of CDAD with use of PPIs in the drug labels.

NGC's Sister Resources